Neutrophilic Panniculitis in a Pediatric Patient Receiving Ponatinib
Abstract
Ponatinib is a tyrosine kinase inhibitor used in children with chronic myeloid leukemia. We report a case of neutrophilic panniculitis following ponatinib administration in a child. With the expanded use of immunomodulatory medications in the pediatric population, this report aims to expand knowledge regarding potential drug-related adverse events and the inclusion of ponatinib-related adverse events in the differential diagnosis of neutrophilic panniculitis.
Fields of Study & Subjects
Chronic Myeloid Leukemia Treatments
Autoimmune and Inflammatory Disorders
Chronic Lymphocytic Leukemia Research
Publication details
- Journal / source
- Pediatric Dermatology
- Publisher
- Wiley
- Volume
- 43
- Issue
- 5
- Pages
- 1238-1240
- Publication date
- 18 May 2026
- Language
- EN